ccRCC is currently treated with anti-angiogenic drugs, such as the Tyrosine-Kinase-Inhibitors (TKI) Sorafenib and Sunitinib, to counter the effects of the HIF1/2α accumulation occurring upon pVHL inactivation. Here, VHL is linked to nonpapillary renal cell carcinoma.